Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

This is the largest-ever primary fundraise in the Indian diagnostics segment and the first private equity round for Neuberg ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

Find insight on Zydus Lifesciences, Biotech and more in the latest Market Talks covering the Health Care sector.

Plus, readers’ letters, family notices, this week’s events guide, mart prices, Remember When and much more. All in this ...

GSK announced on Friday that the US Food and Drug Administration (FDA) has accepted its regulatory application for a ...

Neuberg Diagnostics, one of India’s leading diagnostics chains, has secured Rs 940 crores in investment from Kotak Alt, ...